Oculis Holding AG (OCS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 22.61 |
Market Cap | 922.47M |
Revenue (ttm) | 699.61K |
Net Income (ttm) | -74.70M |
EPS (ttm) | -1.81 |
PE Ratio (ttm) | -12.51 |
Forward PE | -6.69 |
Analyst | Buy |
Ask | 22.72 |
Volume | 62,311 |
Avg. Volume (20D) | 68,541 |
Open | 22.88 |
Previous Close | 22.64 |
Day's Range | 22.61 - 23.00 |
52-Week Range | 10.55 - 23.08 |
Beta | 0.01 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye ...
Analyst Forecast
According to 5 analyst ratings, the average rating for OCS stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 28.09% from the latest price.
Next Earnings Release
Analysts project revenue of $243.36K, reflecting a 16.64% YoY growth and earnings per share of -0.38, making a 0.00% YoY.